Skip to content

Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease

Clinical Safety and Efficacy of FMT in the Treatment of Alzheimer's Disease

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06920212
Enrollment
30
Registered
2025-04-09
Start date
2024-10-01
Completion date
2025-12-31
Last updated
2025-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fecal Microbiota Transplantation

Brief summary

To investigate the clinical safety and efficacy of FMT in AD patients, as well as the changes in the gut microbiota of AD patients before and after FMT.

Interventions

PROCEDUREFMT capsule

Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.

Sponsors

Shanghai 10th People's Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* The patients (aged 50-85 years) exhibited cognitive decline persisting for over six months; * Primarily characterized by recent memory impairment and accompanied by reduced daily living abilities; * MMSE scores ranging from 3 to 26; * MRI findings revealed atrophy in the medial temporal lobe, hippocampus, and cerebral cortex, along with widened sulci and fissures.

Exclusion criteria

* Patients were excluded if they had severe visual, hearing, or language impairments; * Tumors; * hepatic/renal dysfunction. * with conditions mimicking AD symptoms-such as normal pressure hydrocephalus, vascular dementia (VD or VaD); * Parkinson's disease dementia (PDD)-were also excluded; * patients who had participated in clinical drug trials within the past 30 days or consumed folate and vitamin B12 at doses exceeding twice the recommended intake were ineligible.

Design outcomes

Primary

MeasureTime frameDescription
Efficacy endpoints0, 1month, 2months, 3months, 6monthsChanges in scores on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
Changes in gut microbiota0, 1month, 2months, 3month, 6monthsGut metagenomic sequencing was performed to conduct OTU (Operational Taxonomic Unit) clustering and taxonomic analysis, comparing alterations in patients' intestinal flora before and after FMT.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026